Trial Profile
Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 15 Jun 2019 Results evaluating patient baseline characteristics prior to and treatment response on different disease manifestations in cohort of ankylosing spondylitis with IBD copared to an without IBD, presented at the 20th Annual Congress of the European League Against Rheumatism.
- 16 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2013 Planned end date changed from 1 Dec 2013 to 1 May 2014 as reported by ClinicalTrials.gov.